Replies to post #943 on SurModics Inc (SRDX)

[DewDiligence]

That analyst is out to lunch, IMO. Visudyne is a barbaric relic; I give it zero chance of making a meaningful comeback.

NVS seems to agree—there was nary a peep about Visudyne in NVS’ long PR announcing the approval of Lucentis in Europe (#msg-16445106).

[shears]

Perhaps controlled elution of lucentis from the surface of an implantable device rather than high dose intermittant bolus of the drug via injection would also lower the stroke risk?